Prof. P. Whiting
Paul Whiting is Chief Scientific Officer of the Alzheimer’s Research UK UCL Drug Discovery Institute (AR-UK UCL DDI). Established in 2015, its goal is to facilitate the rapid translation of knowledge generated at UCL and partners towards novel therapeutics for neurodegenerative diseases: the dementias, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotropic lateral sclerosis. The AR-UK UCL DDI will consist of a team of ~ 25 chemists and biologists tasked with the goal of developing and validating therapeutics for neurodegenerative diseases suitable for progression towards clinical trials.
The Lead Academic Scientists for the Institute are UCL Profs Giampietro Schiavo, John Hardy and Bart de Strooper.
The AR-UK UCL DDI is
interested in hearing your ideas regarding new hypotheses and drug targets for
therapies for neurodegenerative diseases, and actively seeks opportunities for
collaboration. Please contact email@example.com
or visit our the Alzhmeier's Research website